Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of P2X7 Receptor Occupancy by Zanvipixant
NCT03437590Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanvipixant in bipolar disorder (BD) and major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of P2X7 Receptor Occupancy. Started Mar 2018; status: completed.
02
Drugs
zanvipixant
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03437590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437590.